包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | JBJ-09-063 TFA is a mutant-selective allostericEGFRinhibitor withIC50s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM forEGFRL858R,EGFRL858R/T790M,EGFRL858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 TFA effectively reducesEGFR,Aktand ERK1/2 phosphorylation. JBJ-09-063 TFA is effective acrossEGFRtyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 TFA can be used for researching EGFR-mutant lungcancer[1]. | ||||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||||
体外研究 (In Vitro) | JBJ-09-063 is remarkably effective at inhibiting cell growth and leads to a significant increase in apoptosis, even though H3255GR cells are resistant to gefitinib as a single agent, as they contain an EGFR T790M mutation[1]. | ||||||||||||||||||
体内研究 (In Vivo) | JBJ-09-063 (3 mg/kg i.v., 20 mg/kg p.o.) exhibits favorable pharmacokinetics properties and is sufficiently stable to deliver good efficacy upon oral dosing[2].
| ||||||||||||||||||
分子量 | 670.67 | ||||||||||||||||||
性状 | Solid | ||||||||||||||||||
Formula | C33H30F4N4O5S | ||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(149.10 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |